ORIC News and Press, Oric Pharmaceuticals Inc. From 02/24/26

2026-02-24 11:03:49 ET Robert Burns from H.C. Wainwright issued a price target of $25.00 for ORIC on 2026-02-24 15:50:34. The adjusted price target was set to $25.00. At the time of the announcement, ORIC was trading at $13.2661. The overall price target consensus is at ...

2026-02-18 17:14:59 ET ORIC Pharmaceuticals, Inc. (ORIC) Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 2:30 PM EST... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034 [1] , fueled by a structural shift where institutional capital is abandoning discovery-stage...

2026-01-20 13:36:46 ET ... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Jan. 14, 2026 /CNW/ --  Equity-Insider.com News Commentary – The precision oncology market is ...

2026-01-13 16:35:57 ET ORIC Pharmaceuticals, Inc. (ORIC) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM EST... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healt...

2026-01-12 09:27:53 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript ORIC Pharmaceuticals GAAP EPS of -$0.33 beats by $0.08 Seeking Alpha...

Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstr...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive offic...